Quantum Genomics is a biopharmaceutical company specializing in the development of a new drug class for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure. Quantum Genomics research programs are based on the brain inhibition mechanism of Aminopeptidase A : BAPAI (Brain Aminopeptidase A Inhibitors), a truly innovative triple-action therapeutic platform developed by the academic research laboratories of the Collège de France and INSERM. Quantum Genomics is the only biopharmaceutical company specializing in the development of a new drug class based on the central action mechanism of Aminopeptidase A inhibition.